


# PROCEEDINGS

Stee  
RC  
261  
A1  
A42  
v. 38

**EIGHTY-EIGHTH ANNUAL MEETING**

American Association for  
Cancer Research



**APRIL 12-16, 1997**

**SAN DIEGO, CA**

**VOLUME 38 ■ MARCH 1997**

**DOCKET  
ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

PROCEEDINGS OF THE  
AMERICAN ASSOCIATION FOR CANCER RESEARCH

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

**Executive Director and  
Director of Publications**  
Margaret Foti

**Publications Staff  
Associate Director  
of Publications**  
Mary Anne Mennite

**Manager, Editorial Services**  
Heide M. Pusztay

**Staff Editors**  
Michael J. Beveridge  
Kathleen C. Assenmacher  
Pamela R. Arnold  
Laurie B. Baker  
Ronald M. Vitale

**Staff Assistant**  
Mary Ellen Piring

**Administrative Coordinator**  
Holly M. Haskins

**Senior Editorial Assistant**  
Theresa A. Griffith

**Editorial Assistants**  
Valerie L. Samuel  
Andrea Conrad  
Cecilia Gallo  
Brenda Roberson

**Marketing Coordinator**  
Robert B. O'Malley

**Administrative Staff  
Director of Administration**  
Adam D. Blistein

**Controller**  
Joan D. Ritchie

**Coordinator, Financial Operations**  
George L. Moore

**Manager, Meetings and Exhibits**  
Jeffrey M. Ruben

**Meeting Planner**  
Carole L. Kanoff

**Public Information Coordinator**  
Jenny Anne Horst-Martz

**Assistant to the Executive Director**  
Ruth E. Fortson

**Membership Development Coordinator**  
Robin E. Felder

**Administrative Assistant**  
Margaret A. Pickels

**Systems Specialist**  
Lydia I. Rodriguez

**Accountant I**  
Monica Storione

**Staff Assistants**  
Jennifer S. Roberts  
Maria M. Edstrom

**Meetings Assistant**  
Jinhui Yun

**Financial Assistant**  
Jeriesha L. Williams

**Secretary**  
Malika L. Wright

**Editorial Assistant**  
Diana F. Certo

**Office Clerk**  
James J. Waters

**Data Entry Clerk**  
Robert A. Simms II

**Officers**

Louise C. Strong, *President*  
Donald S. Coffey, *President-Elect*  
Bayard D. Clarkson, *Treasurer*  
Joseph R. Bertino, *Immediate Past President*  
Edward Bresnick, *Past President*  
Margaret Foti, *Executive Director*

**Board of Directors**

*Term Expiring 1997*  
Webster K. Cavenee  
Philip C. Hanawalt  
Stanley J. Korsmeyer  
Thea D. Tlsty

*Term Expiring 1998*  
Clara Derber Bloomfield  
Michael M. Gottesman  
Ann R. Kennedy  
Frederick P. Li

*Term Expiring 1999*  
Susan P.C. Cole  
Eric R. Fearon  
Stephen H. Friend  
Waun Ki Hong

Address inquiries to the Office of the American Association for Cancer Research, Inc. (AACR), Public Ledger Building, Suite 826, 150 S. Independence Mall West, Philadelphia, PA 19106-3483 [Telephone: (215) 440-9300; FAX: (215) 440-9313].

The *Proceedings of the American Association for Cancer Research* is printed for the AACR by Cadmus Journal Services, Linthicum, MD 21090-2908 and included in member subscriptions to the journals *Cancer Research*, *Cell Growth & Differentiation*, *Cancer Epidemiology, Biomarkers & Prevention*, and *Clinical Cancer Research* and in nonmember subscriptions to *Cancer Research*. Volume 38 of the *Proceedings of the American Association for Cancer Research* (ISSN 0197-016X) succeeds Volume 37 of the *Proceedings of the American Association for Cancer Research*. The *Proceedings* may be obtained at a price of \$45.00 through registration at the annual meeting of the American Association for Cancer Research, April 12-16, 1997, or ordered by writing to: *Proceedings of the American Association for Cancer Research*, P.O. Box 3000, Denville, NJ 07834 [Telephone: (800) 875-2997 or (201) 627-2427; FAX: (201) 627-5872]. Add \$6.00 for shipping for orders from outside the U.S.; expedited delivery rates are available upon request.

The *Proceedings of the American Association for Cancer Research* is copyrighted © 1997 by the AACR. All rights reserved. Redistribution or resale of the *Proceedings* or of any materials in the *Proceedings*, whether in machine readable, other electronic or any other form, is prohibited. Reproduction for advertising or promotional purposes, or republication in any form, may be permitted only under license from the AACR. Any reproduction, whether electronic or otherwise, of abstracts beyond that permitted by copyright law must be authorized in writing in advance by the AACR. Requests to reproduce abstracts will be considered on an individual basis and permission may be granted contingent upon payment of an appropriate fee. Reproduction requests must include a brief description of intended use. Third parties should also obtain the approval of the authors before corresponding with the AACR. Failure to comply with the foregoing restrictions and unauthorized duplication of any portion of these materials are a violation of applicable laws and may be subject to criminal prosecution and civil penalties.

No responsibility is accepted by the Editors, by the American Association for Cancer Research, Inc., or by the AACR for any errors or omissions in the *Proceedings*.

(CD31 staining) in CGP 53716 treated with mice. Collectively, these data suggest that inhibition of tumor stroma formation and angiogenesis following CGP 53716 treatment results in growth inhibition of H226 carcinoma in the lung.

**#4246** CGP 57148B, a protein-tyrosine kinase inhibitor with potential for the treatment of Bcr-Abl positive leukemias and diseases involving deregulation of PDGF receptor and c-Kit tyrosine kinases. Buchdunger, E., Zimmermann, J., Mett, H., Müller, M., Law, N., Cioffi, C., Druker, B., and Lydon, N. *Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Ltd., CH-4002 Basel, Switzerland, Ciba Pharmaceuticals Division, Ciba-Geigy Ltd., Summit, New Jersey 07901, Oregon Health Sciences University, Portland, Oregon 97201*

CGP 57148B has been identified as a potent protein-tyrosine kinase inhibitor with selectivity for the Abl and PDGF receptor tyrosine kinases. Cellular proliferation and tumor growth of Bcr-Abl or v-Abl expressing cells were specifically inhibited by this compound. CGP 57148B selectively inhibited PDGF-mediated cellular events such as PDGF receptor autophosphorylation, inositol phosphate formation and *c-fos* induction. The compound was a potent inhibitor of PDGF-mediated growth of *v-sis* transformed BALB/c 3T3 cells and PDGF-stimulated proliferation of A10 rat aortic smooth muscle cells. *In vivo*, CGP 57148B inhibited growth of a number of PDGF-dependent tumors. Combination of CGP 57148B with cytotoxic agents resulted in tumor regression and cures, with different xenografts being sensitive to different drug combinations. Amongst Type III receptor tyrosine kinases, CGP 57148B was found to potently inhibit the SCF receptor, c-Kit, but not the related c-Fms, Flt-3 and Flt-1 tyrosine kinases. Increasing evidence suggests that inappropriate receptor signaling by c-Kit may be involved in a number of cancers, including small cell lung cancer (SCLC). Interestingly, tumor growth of NCI-H69 and NCI-H209 SCLC lines was sensitive to inhibition by CGP 57148B which is compatible with the inhibition of the c-Kit tyrosine kinase. Taken together, these results suggest that CGP 57148B is a signal transduction inhibitor which might have therapeutic potential for the treatment of Ph+ leukemias as well as diseases which involve abnormal activation of PDGF receptor and c-Kit tyrosine kinases.

**#4247** Cytotoxicity and phosphotyrosine effects of c-src kinase inhibition by substituted pyridopyrimidine tyrosine kinase inhibitors in human colon carcinoma cell lines. Kraker, A.J., Moore, C.W., Amar, A.M., Shen, C.S., Nelson, J., Slintak, V., Fry, D.W., Lu, G., Panek, R., Klutchko, S., and Hamby, J. *Parke-Davis Pharm Res. Div. of Warner-Lambert Co., Ann Arbor, MI 48105*

Tyrosine kinase inhibition has been identified as a potential therapeutic strategy in neoplastic disease. Potent c-src kinase inhibitors ( $IC_{50}$ =9nM in isolated c-src assay for 6-(2,6-dichloro-phenyl)-2-[4-(2-diethylamino-ethoxy)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one dihydrochloride (PD166285, **A**) are described. Src family members *fyn*, *lyn*, and *lck* are also potently inhibited *in vitro*. **A** causes growth delay on plastic with  $IC_{50}$  values of 140nM for HT-29, 426nM for HCT-8 and 270nM for SW-620 cell lines. In soft agar clonogenic assays with 2 day treatment followed by drug removal, **A** gave  $IC_{50}$  values of 1.8  $\mu$ M (HT-29), 780nM (HCT-8), and 330nM (SW-620). Phosphotyrosine (P-Y) content of focal adhesion kinase (FAK) and paxillin (known substrates of c-src) is reduced at sub- $\mu$ M concentrations in HT-29 cells treated with **A** for 2 hours and then mitogenically stimulated. In a fibroblast cell line overexpressing epidermal growth factor receptor (EGFR) and c-src, **A** is a specific c-src inhibitor (reducing FAK and c-src P-Y) compared to EGFR kinase activity (receptor P-Y). Because of potent kinase inhibition, selectivity, and cellular signaling effects of these compounds, *in vivo* studies are underway.

**#4248** CP-358,774: A selective EGFR kinase inhibitor with potent antiproliferative activity against HN5 head and neck tumor cells. Iwata, K., Miller, P.E., Barbacci, E.G., Arnold, L., Doty, J., DiOrto, C.I., Pustilnik, L.R., Reynolds, M., Thelemann, A., Sloan, D., and Moyer, J.D. *Oncogene Science Inc., Uniondale, NY 11553-3649, Pfizer Central Research, Groton, CT 06340*

CP-358,774 is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK), an activity which is overexpressed in many carcinomas. CP-358,774 inhibits isolated human EGFR TK with an  $IC_{50}$  of 2 nM, and reduces EGFR autophosphorylation in MDA-MB-468 tumor cells in culture with an  $IC_{50}$  of 20 nM. EGFR TK is >1000-fold more sensitive to CP-358,774 than other TKs such as human c-src, insulin receptor, insulin-like growth factor receptor, or v-abl. As a further indication of selectivity, EGF-induced tyrosine phosphorylation of SHC proteins in HN5 cells is completely blocked by CP-358,774, whereas the insulin-induced phosphorylation of IRS-1 is unaffected. CP-358,774 inhibits EGF-stimulated mitogenesis in Fischer rat embryo cells with an  $IC_{50}$  of 70 nM, but does not similarly inhibit mitogenesis stimulated by platelet derived growth factor, insulin-like growth factor, or basic fibroblast growth factor, which also act through transmembrane receptors with TK activity. The proliferation of HN5 cells, which overexpress EGFR, is inhibited by CP-358,774 at 50 nM, and completely blocked at 250 nM. Pretreatment of athymic mice with CP-358,774 (100 mg/kg) completely inhibits EGF-induced autophosphorylation of human EGFR in HN5 tumor xenografts and of EGFR in mouse liver. This inhibitor has potential for the treatment of tumors that are dependent on the EGFR pathway for proliferation.

**#4249** Therapy of human carcinomas in athymic mice by inhibition of EGF receptor-mediated signal transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects. Pollack, V.A., Savage, D.M., Baker, D.A., Tsaparikos, K.E., Sloan, D.E., Barbacci, E.G., Pustilnik, L.R., Smolarek, T.A., Davis, J.A., Vaidya, M.P., and Iwata, K. *Dept. of Cancer, Pfizer Central Research, Groton, CT 06340, Oncogene Science, Inc., Uniondale, NY 11553*

Tyrosine phosphorylation of EGF receptors is an important early event in signal transduction and tumor cell replication. We devised an *ex vivo* assay to quantitate EGF-specific tyrosine phosphorylation in human tumors obtained as s.c. xenografts in athymic mice. Using an enzyme-linked immunosorbent assay (ELISA), we observed reproducible  $ED_{50}$ 's and have used this assay to describe the extent and duration of drug action *in vivo*. CP-358774 is an effective, orally active inhibitor of EGFR tyrosine phosphorylation ( $ED_{50}$ = 10 mg/kg po). It has significant duration of action, producing, on average, 70% inhibition of EGFR-PY over a 24-hr period. Most importantly, we observed that inhibition of EGFR-PY in an *ex vivo* assay effectively correlates with the potency and degree of inhibition of EGFR-dependent human HN5 tumor growth in a xenograft therapy model ( $ED_{50}$ = 10 mg/kg qd X 5). These data suggest that CP-358774 may be an important new agent for therapy of EGFR-overexpressing human cancers.

**#4250** Pyrido[d]pyrimidine inhibitors of the tyrosine kinase activity of the EGF receptor: A binding model and structure-activity relationships for soluble analogues. Denny, W.A., Palmer, B.D., Rewcastle, G.W., Thompson, A.M., Bridges, A.J., Doherty, A.M., Fry, D.W., Nelson, J.M., Rubin, J.R., Showalter, H.D.H., and Trumpp-Kallmeyer, S. *Cancer Society Res. Lab, University of Auckland, Private Bag 92019, Auckland, New Zealand, Parke-Davis Pharmaceutical Res., Division of Warner-Lambert Co., 2800 Plymouth Rd., Ann Arbor, MI 48105*

4-Anilino-pyrido[d]pyrimidines are potent, selective inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), binding at the ATP site with  $IC_{50}$  values down to 8 pM. They are of interest as anticancer drugs, since EGFR is over-expressed in many cancers and associated with poor clinical prognosis. A model for their binding to the EGFR was constructed from the catalytic subunit of the related cAMP-dependent protein kinase, and from structure-activity data. This attributes their high selectivity to binding of the 4-anilino ring in a hydrophobic pocket of composition unique to the EGFR. The 6- and 7-positions of the pyrido[d]pyrimidines occupy the entrance of the ATP binding pocket, with the 7-position pointing towards the ribose binding site of ATP. In agreement with this, analogues with weakly basic solubilising groups at the 6- or 7-positions retain potent inhibitory activity towards EGFR. They are also potent inhibitors of EGFR auto-phosphorylation in A431 cells. Examples evaluated against murine colon 38 tumors and human tumor xenografts in mice gave substantial growth delays.

**#4251** ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Woodburn, J.R., Barker, A.J., Gibson, K.H., Ashton, S.E., Wakeling, A.E., Curry, B.J., Scarlett, L., and Henthorn, L.R. *Zeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, U.K. SK10 4TG*

Epidermal growth factor receptor (EGFR) is overexpressed in a wide variety of solid human cancers including non-small cell lung, breast, head and neck, bladder and ovarian carcinomas. ZD1839, an anilinoquinazoline, is a potent inhibitor (0.02 micromolar) of the EGFR tyrosine kinase *in vitro* and of the EGF-stimulated growth of KB oral carcinoma cells in culture (0.08 micromolar). ZD1839 has excellent oral bioavailability and shows antitumor activity in a broad range of human solid tumor xenografts implanted in nude mice in the dose range 12.5 - 200 mg/kg once per day orally. Sensitive tumors include A431 vulval, KB oral, A549 NSCLC, DU145 prostate, HT29, HCT15, CR10 and LoVo colorectal, and HX62 ovarian. Antitumor effects range from reduced growth rate to stasis; with marked regressions seen in some tumors. Therapy for up to 4 months in nude mice is well tolerated. On the basis of these exciting pre-clinical data ZD1839 has been selected for clinical development.

**#4252** Novel benzoylacetylenic compounds: Potent and selective EGF receptor tyrosine kinase inhibitors. Suzuki, T., Kitano, Y., Ohya, J., Umeki, H., Inokawa, H., Kawahara, E., Nakamura, H., Takayanagi, H., and Hara, H. *Pharmaceuticals Lab., Yokohama Research Center, Mitsubishi Chemical Co., Yokohama, Japan*

Inhibition of oncogenic tyrosine kinases is a potential approach for the treatment of cancer. We have synthesized a novel series of benzoyl acetylenic compounds as potent and selective inhibitors of EGF receptor tyrosine kinase. We found that one of these compounds, DAB-720, has excellent biological activities *in vitro* and *in vivo* studies. We show here the structure-activity relationships of these derivatives and biological profiles of DAB-720. Using a panel of protein kinases including EGF receptor, PDGF receptor, c-src, lck and PKC, DAB-720 displayed selective inhibitory activity against EGF receptor with  $IC_{50}$  of 0.070  $\mu$ M and little or no inhibition for the other kinases at 50  $\mu$ M, except lck for which DAB-720 had an  $IC_{50}$  of 16  $\mu$ M. Autophosphorylation of EGF receptor in A431 cells and of HER2/Erb B2 in BT474 cells were also inhibited over 50% at 5  $\mu$ M and 10  $\mu$ M respectively. The  $IC_{50}$  for KB cell growth was 0.76  $\mu$ M. *In vivo* study significant growth inhibition of KB xenograft in nude mice was demonstrated by 30 mg/kg intraperitoneal administrations of DAB-720.